Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 5, 1997, Pages 507-512

  Cliang, Esther H ^a   Hao, Zhengmei ^c   Murphy, Gloria ^d   Rait, Antonina ^d   Fee Jr , Willard E ^b   Sussman, Howard H ^c   Ryan, Patricia ^a   Chiang, Yawen ^d   Pirollo, Kathleen F ^d  

^a Department of Surgery   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE G1 PHASE; FLOW CYTOMETRY; GENETICS; HEAD AND NECK TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MUTATION; RADIATION DOSE; XENOGRAFT;

PROTEIN P53;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; G1 PHASE; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030611155     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900050055007     Document Type: Article

References (45)

1. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993:85:95-111.
2. Awan AM, Vokes EE, Weichselbaum RR. Recent advances in radiation therapy for head and neck cancer. Hematol Oncol Clin North Am. 1991;5: 635-655.
3. American Cancer Society. American Cancer Society Facts and Figures. Washington, DC: American Cancer Society; 1993. Publication 93-400.
4. American Joint Committee on Cancer. Manual for Staging of Cancer. 2nd ed. Philadelphia, Pa: JB Lippincott; 1983:25-54.
5. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991;351:453-456.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
7. Lowe SW, Bodie S, Bardeesy N, et al. Apoptosis and prognostic significance of p53 mutation. Cold Spring Harb Symp Quant Biol. 1994:59:419-426.
8. Newcomb EW. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma. 1995;17:211-221.
9. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995;13:1009-1022.
10. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993;119:1118-1122.
11. Brachman DG. Molecular biology of head and neck cancer. Semin Oncol. 1994; 21:320-329.
12. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993:362:847-848.
13. Clarke AR, Purdie ÇA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993:362:849-852.
14. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wildtype p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991:353:345-347.
15. Lowe SW, Bodis S, McClatchey A, et al. p53 status and efficacy of cancer therapy in vivo. Science. 1994:266:807-810.
16. Kastan MB, Onyekwere 0, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51: 6304-6311.
17. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992; 89:7491-7495.
18. Kastan MB, Zhan Q, EI-Delry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992:7:587-597.
19. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995:92:8493-8497.
20. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356:215-221.
21. Lee JM, Bernstein A. p53-mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA. 1993:90:5742-5746.
22. O'Conner PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 1993;53:4776-4780.
23. Mcllwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994:54:3718-3722.
24. Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Cell Biol. 1995:6:590-595.
25. dayman GL, EI-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995:55:1-6.
26. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiât Oncol Biol Phys. 1988:15:575-579.
27. Smith TA, McHaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet. 1993;5:397-402.
28. Trapnell BC. Adenoviral vectors for gene transfer. AdvDrug Delivery Rev. 1993; 12:185-199.
29. Mittereder N, Yei S, Bachurski C, et al. Evaluation of the efficacy and safety of in vitro adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther. 1994:5:717-729.
30. Janat MF, Srivastava S, Devadas K, Chin GA, Pirollo KF, Chang EH. Inhibition of retinoblastoma (RB) protein phosphorylation by the combined effect of interferon-7 and tumor necrosis factor-a. Mol Cell Differentiation. 1994;2:241-253.
31. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 1992:52:6390-6393.
32. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. In press.
33. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995:55:1643-1648.
34. 1 checkpointdeficient and checkpoint-competent cells. Cancer Res. 1995:55:1639-1642.
35. 2/M by p53. Oncogene. 1995:10:109-115.
36. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995:92:8493-8497.
37. Lowe SW. Cancer therapy and p53. Curr Opin Oncol. 1995;7:547-553.
38. Wu SG, EI-Deiry WS. p53 and chemosensitivity. Nat Med. 1996:2:255-256.
39. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 1996:2:804-810. .
40. Aas T, Borresen A-L, Geisler S, et al. Specific p53 mutations are associated with de novo resistance in doxorubicin in breast cancer patients. Nat Med. 1996:2:811-814.
41. 2/M arrest and apoptosis. Nat Med. 1996:2:72-79.
42. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996:56:892-898.
43. Srivastava S, Tong YA, Devadas K, et al. Detection of both mutant wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene. 1992:7:987-991.
44. Liu T-H, EI-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;15:3117-3122.
45. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.